Todd Tushla | executive |
Kevin Gorman | executive |
Matthew Abernethy | executive |
Eric Benevich | executive |
Eiry Roberts | executive |
Paul Matteis | analyst |
Tazeen Ahmad | analyst |
Brian Skorney | analyst |
Philip Nadeau | analyst |
Brian Abrahams | analyst |
Stephen Sloan | analyst |
Joshua Schimmer | analyst |
Anupam Rama | analyst |
Carter L. Gould | analyst |
Jay Olson | analyst |
Myles Minter | analyst |
Michael Riad | analyst |
Danielle Brill | analyst |
Laura Chico | analyst |
Kyle Gano | executive |
Sumant Kulkarni | analyst |
Malcolm Hoffman | analyst |
Leonid Timashev | analyst |
Mohit Bansal | analyst |
Uy Ear | analyst |
Good day, and welcome to Neurocrine Biosciences Year-End and Fourth Quarter Results Call. [Operator Instructions]. Please note today's call will be recorded, and I'll be standing by if you should need any assistance.
It is now my pleasure to turn the conference over to Todd Tushla, Vice President of Investor Relations. Please go ahead.